These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25085753)

  • 21. Bad expression predicts outcome in patients treated with tamoxifen.
    Cannings E; Kirkegaard T; Tovey SM; Dunne B; Cooke TG; Bartlett JM
    Breast Cancer Res Treat; 2007 Apr; 102(2):173-9. PubMed ID: 17004114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer.
    Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Int J Cancer; 2001 Jul; 95(4):247-54. PubMed ID: 11400118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.
    Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
    Breast Cancer Res Treat; 2011 Feb; 126(1):93-9. PubMed ID: 21184268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.
    Linderholm BK; Hellborg H; Johansson U; Skoog L; Lehtiö J
    Breast Cancer Res Treat; 2011 Jan; 125(2):457-65. PubMed ID: 21110084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
    Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and an advanced stage of breast cancer.
    Kuo HT; Hsu HT; Chang CC; Jiang MC; Yeh CM; Shen KH; Hsu PC; Tai CJ
    Pol J Pathol; 2013 Oct; 64(3):163-9. PubMed ID: 24166600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
    Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolving role of oestrogen receptor beta in clinical breast cancer.
    Speirs V
    Breast Cancer Res; 2008; 10(5):111. PubMed ID: 18831727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
    Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
    Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease related indicators for a proper choice of adjuvant treatments.
    Hayes DF
    Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SIRT2: tumour suppressor or tumour promoter in operable breast cancer?
    McGlynn LM; Zino S; MacDonald AI; Curle J; Reilly JE; Mohammed ZM; McMillan DC; Mallon E; Payne AP; Edwards J; Shiels PG
    Eur J Cancer; 2014 Jan; 50(2):290-301. PubMed ID: 24183459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer.
    Kenny FS; Willsher PC; Gee JM; Nicholson R; Pinder SE; Ellis IO; Robertson JF
    Breast Cancer Res Treat; 2001 Jan; 65(2):135-44. PubMed ID: 11261829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.